Oncolytics Biotech Inc.

447 articles with Oncolytics Biotech Inc.

• Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

  5/26/2020

  Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced the publication of an electronic-poster with clinical data from the Company's AWARE-1 window-of-opportunity breast cancer study.

• Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

  5/14/2020

  Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple myeloma patients treated with pelareorep and carfilzomib

• Oncolytics Biotech® to Present at the RBC Global Healthcare Conference

  5/13/2020

  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey , President & CEO of Oncolytics Biotech, will present during the RBC Global Healthcare Conference at 1:55 pm Eastern Time on Wednesday , May 20

• Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights

  5/8/2020

   Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended March 31, 2020 . All dollar amounts are expressed in Canadian currency unless otherwise noted.

• Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

  5/8/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020. 

• Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting

  5/4/2020

  AWARE-1 data demonstrate pelareorep-mediated priming of an adaptive immune response

• Oncolytics Biotech® Announces Changes to Annual General Meeting in May 7, 2020.

  4/30/2020

  Oncolytics Biotech® Inc., announced that in light of the ongoing COVID-19 pandemic, it is taking precautionary measures for its upcoming 2020 Annual General Meeting to be held at 4:30 p.m. on May 7, 2020..

• Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

  4/17/2020

  Oncolytics Biotech® Inc. provided an update on the potential impact of COVID-19 on the Company's clinical and business operations.

• Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

  4/2/2020

  93.3% clinical benefit rate 86% improvement over historical overall survival rates at recommended phase 2 dose Pelareorep stimulates robust antitumor adaptive immune response   [02-April-2020]   SAN DIEGO and CALGARY, Alberta , April 2, 2020 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intr

• Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

  3/24/2020

  Oncolytics Biotech® Inc. announced a favourable assessment from the Safety Committee following review of data from the window of opportunity study in early-stage breast cancer, known as AWARE-1.

• Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

  3/5/2020

  Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced its financial results and operational highlights for the quarter and year ended December 31, 2019.

• Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

  2/28/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Thursday, March 5, 2020 following release of its fourth quarter and year end 2019 financial results.

• Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

  1/27/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that a poster presentation highlighting statistically significant data identifying CEACAM6 as a prospective biomarker for pelareorep in the treatment of pancreatic cancer.

• Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

  1/22/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today stated that the previously announced abstract for a poster to be presented at the 2020 Gastrointestinal Cancers Symposium sponsored by ASCO in San Francisco, has been published

• Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

  1/13/2020

  Safety cohort in the investigator sponsored multiple myeloma study, receiving both carfilzomib and Opdivo®, is now complete and pelareorep will be added to the combination in the next cohort in the coming weeks

• Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

  1/9/2020

  Oncolytics Biotech® Inc., currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced that ROTH Capital Partners will conduct a Key Opinion Leader call for their institutional clients.

• Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

  12/12/2018

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo®(nivolumab) to treat relapsed multiple myeloma patients.

• Oncolytics Biotech® Announces Publication of Positive Clinical Results for Pelareorep in Abstract for ESMO 2018 Congress

  10/11/2018

  Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data

• Oncolytics Biotech® Announces a Publication Demonstrating That Intravenously Delivered Oncolytic Viruses Effectively Target Tumors Even in the Presence of Neutralizing Antibodies

  10/2/2018

  Oncolytics Biotech® Inc. today announced publication of important research in the peer-reviewed journal Cancer Immunology Research.

• Oncolytics Biotech® Collaborates with SOLTI to Conduct a Window of Opportunity Study in Breast Cancer with Pelareorep

  9/12/2018

  Oncolytics Biotech® Inc. today announced a clinical collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer.